|1.||Boyd, Marie: 8 articles (06/2013 - 02/2005)|
|2.||Mairs, Robert J: 7 articles (06/2013 - 02/2005)|
|3.||Pacak, Karel: 7 articles (11/2012 - 02/2003)|
|4.||Kim, Jae-Won: 6 articles (09/2014 - 01/2008)|
|5.||Cho, Soo-Churl: 6 articles (09/2014 - 01/2008)|
|6.||Matthay, Katherine K: 6 articles (12/2012 - 08/2008)|
|7.||Jordan, Jens: 6 articles (03/2008 - 01/2002)|
|8.||Luft, Friedrich C: 6 articles (03/2008 - 01/2002)|
|9.||Tank, Jens: 6 articles (03/2008 - 01/2002)|
|10.||Robertson, David: 6 articles (07/2007 - 12/2002)|
|1.||Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder)
02/01/2012 - "Pharmacologic and animal studies have strongly implicated the norepinephrine transporter (NET) in the pathophysiology of attention-deficit/hyperactivity disorder (ADHD). "
03/05/2010 - "Association studies of -3081(A/T) polymorphism of norepinephrine transporter gene with attention deficit/hyperactivity disorder in Korean population."
12/05/2008 - "In a previous study screening 51 candidate genes for association with ADHD in a multi-centre European sample (the IMAGE project), two single nucleotide polymorphisms (SNPs) within the norepinephrine transporter (SLC6A2) gene were found to be associated with attention deficit hyperactivity disorder (ADHD). "
01/01/2008 - "No evidence of an association between norepinephrine transporter gene polymorphisms and attention deficit hyperactivity disorder: a family-based and case-control association study in a Korean sample."
04/03/2015 - "A haplotype of the norepinephrine transporter gene (SLC6A2) is associated with visual memory in attention-deficit/hyperactivity disorder."
10/01/2008 - "This agent is variably delivered into tumor cells by the norepinephrine transporter, but few studies have shown treatments that work to increase norepinephrine transporter activity. "
12/01/2013 - "Biodistribution of (18)F-LMI1195 was compared with (123)I-MIBG in MENX mut/mut rats (n = 6) and correlated with histological tumor volume and norepinephrine transporter (NET) expression. "
05/01/2011 - "Derived from the sympathetic nervous system, this tumor typically expresses the norepinephrine transporter. "
09/01/2010 - "PET imaging of norepinephrine transporter-expressing tumors using 76Br-meta-bromobenzylguanidine."
02/01/2003 - "Because norepinephrine transporter systems have been previously found in MTC, it is conceivable that 6-[(18)F]fluorodopamine PET scanning can be used for the diagnostic localization of this tumor and its metastatic deposits because total and early resection is beneficial to the outcome of the patient."
01/01/2015 - "Despite wide discrepancy in the methodology of the studies reviewed, the following conclusions can be drawn: (1) selective serotonin transporter (SERT), selective noradrenaline transporter (NET), and dual SERT/NET inhibitors are effective against PD depression; (2) selective dopamine transporter (DAT) and dual DAT/NET inhibitors exert an anti-Parkinsonian effect when administered as monotherapy but do not enhance the anti-Parkinsonian actions of L-3,4-dihydroxyphenylalanine (L-DOPA); (3) dual DAT/SERT inhibitors might enhance the anti-Parkinsonian actions of L-DOPA without worsening dyskinesia; (4) triple DAT/NET/SERT inhibitors might exert an anti-Parkinsonian action as monotherapy and might enhance the anti-Parkinsonian effects of L-DOPA, though at the expense of worsening dyskinesia. "
12/01/2014 - "Norepinephrine transporter inhibition with desipramine exacerbates L-DOPA-induced dyskinesia: role for synaptic dopamine regulation in denervated nigrostriatal terminals."
12/01/2012 - "Literature search included the terms adrenergic, noradrenergic, reuptake, inhibitors, analgesia, NET, norepinephrine transporter, and pain using Medline, Google scholar, Web of Knowledge, www.clinicaltrials.gov, and Pharmaprojects (Informa UK Ltd. "
11/11/2010 - "Diaryldiamines with dual inhibition of the histamine H(3) receptor and the norepinephrine transporter and the efficacy of 4-(3-(methylamino)-1-phenylpropyl)-6-(2-(pyrrolidin-1-yl)ethoxy)naphthalen-1-ol in pain."
11/26/2009 - "chi-Conopeptide pharmacophore development: toward a novel class of norepinephrine transporter inhibitor (Xen2174) for pain."
11/02/2006 - "One recently identified conotoxin, MrIA, a 13-residue member of the chi-conotoxin family, inhibits the human norepinephrine transporter (NET) and has potential applications in the treatment of pain. "
01/01/2005 - "The chi-conopeptides MrIA and MrIB are 13-residue peptides with two disulfide bonds that inhibit human and rat norepinephrine transporter systems and are of significant interest for the design of novel drugs involved in pain treatment. "
10/28/2005 - "Cardiac overexpression of the norepinephrine transporter uptake-1 results in marked improvement of heart failure."
03/01/2001 - "The neuronal norepinephrine transporter in experimental heart failure: evidence for a posttranscriptional downregulation."
02/01/2006 - "An impairment of cardiac norepinephrine reuptake through the neuronal norepinephrine transporter promotes depletion of cardiac norepinephrine stores and local cardiac sympathetic activation in heart failure. "
11/01/2003 - "Activity of the uptake-1 norepinephrine transporter as measured by I-123 MIBG in heart failure patients with a loss-of-function polymorphism of the presynaptic alpha2C-adrenergic receptor."
03/01/2014 - "[Protein interacting with kinase Cα mediates the down-regulation of myocardial norepinephrine transporter expression in mice with adriamycin-induced congestive heart failure]."
|4.||N-acetyltalosaminuronic acid (NAT)
|5.||Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)
|6.||Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)
|7.||Levodopa (L Dopa)
|8.||Histamine (Histamine Dihydrochloride)
|9.||Serotonin (5 Hydroxytryptamine)
|4.||Heterologous Transplantation (Xenotransplantation)